Member Info for Hikikomori

No, the placing was announced on the 29th Feb.

It closed around 2.5p on the 28th. Feel free to check.

They can issue almost 69m shares before the 1st of March.

Placings always come at a discount, otherwise you wouldn’t get them away.

Those are the cold hard facts.

Wrong again, the day before the 2p placing the price was above 2p.

So much for researching all weekend.

Prior to the previous placing of 166,250,000 shares in Feb there were 1.175b shares issued.

They can raise 20% in a rolling 12 month period.

So the total they can raise before Feb 2025 is about 235m, of which they’ve already issued over 166m

Happy to be corrected if you want to show how you got to 166m

They don’t have 166m shares left to issue, it’s more like 69m I believe. They would be lucky to raise above 1p given today’s SP.

When you take the costs into account, it would be very unwise.

I wouldn’t class myself as a popular poster, but I am fairly regular poster and a shareholder.

I posted yesterday about the potential positive news flows. Funding is obviously the big unanswered question, but I have absolutely no intention of selling any shares at these silly prices.

I have no idea what has brought about todays selling, but anyone who did have any inside info is hardly likely to disclose it on here, seeing as it would be an offence under market abuse regulation.

Funds essentially, as it’s the lack of them that continues to allow the share price to be dragged down. People are reluctant to invest if they think its likely that they will face dilution.

It’s the same for any small pharma that does not have an income stream, as without cash you can’t run a business or develop new products.

Micky,

There are several potential good news opportunities which may occur in the coming weeks/months to help boost the SP.

The company presented in Boston last week on the CBR platform, about its potential treatment of rare cancers. 

They will also present (after successfully competing for a slot) in early December at the Chemical and Biological Defense Science & Technology Conference in Fort Lauderdale, which is organised by the US Governments ‘Defense Threat Reduction Agency’.

Although they are presenting again on CBR at the second conference, the focus in December is around the reprogramming of Myeloid Cells to Target and Eliminate Emerging Viral Infections. Given they have already been testing this platform in a US government facility, their invitation to present at the conference could be taken as a positive sign that so far the platform has shown promise.

Either of these conferences could bring potential strategic investment or partnership opportunities, and any potential developments on that front arising from the conference last week would not yet be public.

Of course, neither conference could result in any kind of partnership or funding, but it remains a possibility.

Another potential lift to the SP could come as a result of the first patient being treated (perhaps within the next 2-6 weeks, but its really anyone’s guess really as they have said by the end of the year).

There could also be a potential development around the CDX platform, given the recent unexpected progress on that front, after having used Lonza’s bylok bispecific pairing technology to develop a new and improved version of CDX.

For me, despite the slightly disappointing slow march into the clinic, there remains plenty to be positive about, and plenty of scope for a possible increase in the SP.

AIM?

The cash injection comes in March at the start of the planned paediatric trial. It’s essentially recompense for services to be rendered. They can’t know the outcome of the trial as it won’t have even started at that point.

They struck a very similar deal last year for the adult trial due to begin at the end of this year.

I imagine they see it as a good business deal, as they are not the only show in town offering these services and by striking the deal they secure the contract to oversee coordination and analysis of the trial, and if all goes as hoped it will turn out very well for them.

The numbers involved are peanuts in the pharma universe.

I’m very positive on Hemo, but I think people look at the premium paid and try to make much more of it than there really is.

They are gambling on the fortunes of Hemo just like every other investor, and ultimately they can afford to do so.

Dusterinmomg, I would suggest you do your own research on Hemo and the science, rather than relying on posters on this bulletin board. There are many nefarious posters here with their own agenda’s, and therefore I wouldn’t advise you making any investment decisions solely on anything you may have read here.

Fair point about Penn, Stu.

It’s disappointing the change of direction with them, but it’s felt a bit off for a while, and since MD Anderson arrived on the scene (before they were even named), it’s felt like Penn have taken a back seat.

As for the imminently/soon thing, i’m not reading too much into that to be honest.

As you say, let’s see what next week brings.

Today’s update provided no update, other than to repeat what was already known by anyone paying attention.

The price has dropped because of concerns around finances. The cash position was understood by many already, which is to say there is barely any cash left.

The concerns are legitimate, and the update did little to set out how the company will continue to progress.

As a raise is basically of no use, given they have raised the vast majority of what they are allowed already, then I can only assume funding to begin trials is coming via another avenue.

I cannot conceive they would even do the prep work to get to the point of trials starting, let alone actually treat someone, if there wasn’t an established funding avenue available.

So, the position today is the same as it was yesterday.

Nothing will change until we get further updates.

The market has now adjusted and I anticipate this to remain more or less flat for the rest of the day.

Leaks are partly what got us down here in the first place. Better to have news come via RNS.

Also, not sure there is any significant short position on Hemo at the moment tbh

Mr I,

My plan is to hold until something is licensed (assuming what I consider fair value is achieved, and we haven’t been forced to accept a low ball offer to keep the lights on), or until non dilutive funding is granted to progress trials.

At that point I will possibly look to de-risk by offloading a fraction of my holding, but I intend to stay around for the long term as I am excited by the potential in the companies pipeline, particularly CBR.

Yes, in hindsight. These balls are hairy, they ain’t crystal.

But what if i had sold at 6p, and it had then gone to 12p, or higher?

Getting in at the bottom and back out at the top is next to impossible. It’s better to have a plan and exit strategy and stick to it if possible. In my opinion of course, I accept others have different ideas and will buy in and out for a few % here and there.

Many I would guess. Hindsight is a beautiful thing.

Personally, I’m not here to trade the swings in the SP, and my target is significantly north of 6p, so I’ll continue to hold.

How could we forget, you keep reminding us you wished you had sold…

Bingo

It’s absolutely no coincidence that when a much speculated upon RNS didn’t arrive today, the SP dropped 6% within the first hour of trading, and all those new posters we saw at the end of last week all fell silent.

A few may not like to hear it, but JHFH summed it up more or less spot on today.

Anyway, after that initial 6% drop by 9am, the SP stayed more or less flat for the rest of the day. Hardly a catastrophe.

Some posters have today filled this board with negative comments, or petty personal attacks on others.

Some people silently reading along may have been delighted with that, having their work done for them by useful idiots, hoping to see any positive sentiment wiped from the board and the SP dragged back down in turn.

Anyway, I see it like this - If you were happy on Friday evening then there is absolutely no reason to not be happy now, as fundamentally nothing has changed since then.

You have no idea how many hot dinners I’ve had.

I’ll give you a hint, it’s many multiples of the numbers of subscribers your YouTube channel has.

Chart that if you like.

You didn’t even know it wasn’t on AIM mate.

But yeah, well done.